vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and JBG SMITH Properties (JBGS). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $127.6M, roughly 1.3× JBG SMITH Properties). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -2.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -6.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
ESPR vs JBGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $127.6M |
| Net Profit | — | $-45.5M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | -47.5% |
| Net Margin | — | -35.7% |
| Revenue YoY | 143.7% | -2.5% |
| Net Profit YoY | — | 24.0% |
| EPS (diluted) | $0.32 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $127.6M | ||
| Q3 25 | $87.3M | $123.9M | ||
| Q2 25 | $82.4M | $126.5M | ||
| Q1 25 | $65.0M | $120.7M | ||
| Q4 24 | $69.1M | $130.8M | ||
| Q3 24 | $51.6M | $136.0M | ||
| Q2 24 | $73.8M | $135.3M | ||
| Q1 24 | $137.7M | $145.2M |
| Q4 25 | — | $-45.5M | ||
| Q3 25 | $-31.3M | $-28.6M | ||
| Q2 25 | $-12.7M | $-19.2M | ||
| Q1 25 | $-40.5M | $-45.7M | ||
| Q4 24 | — | $-59.9M | ||
| Q3 24 | $-29.5M | $-27.0M | ||
| Q2 24 | $-61.9M | $-24.4M | ||
| Q1 24 | $61.0M | $-32.3M |
| Q4 25 | 50.6% | -47.5% | ||
| Q3 25 | -11.4% | -27.5% | ||
| Q2 25 | 8.6% | -18.4% | ||
| Q1 25 | -34.0% | -44.7% | ||
| Q4 24 | -6.4% | -53.6% | ||
| Q3 24 | -31.0% | -22.4% | ||
| Q2 24 | 3.5% | -24.3% | ||
| Q1 24 | 52.5% | -30.1% |
| Q4 25 | — | -35.7% | ||
| Q3 25 | -35.9% | -23.1% | ||
| Q2 25 | -15.4% | -15.2% | ||
| Q1 25 | -62.2% | -37.9% | ||
| Q4 24 | — | -45.8% | ||
| Q3 24 | -57.2% | -19.8% | ||
| Q2 24 | -83.9% | -18.0% | ||
| Q1 24 | 44.3% | -22.2% |
| Q4 25 | $0.32 | $-0.76 | ||
| Q3 25 | $-0.16 | $-0.48 | ||
| Q2 25 | $-0.06 | $-0.29 | ||
| Q1 25 | $-0.21 | $-0.56 | ||
| Q4 24 | $-0.14 | $-0.70 | ||
| Q3 24 | $-0.15 | $-0.32 | ||
| Q2 24 | $-0.33 | $-0.27 | ||
| Q1 24 | $0.34 | $-0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $75.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.2B |
| Total Assets | $465.9M | $4.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $75.3M | ||
| Q3 25 | $92.4M | $64.4M | ||
| Q2 25 | $86.1M | $61.4M | ||
| Q1 25 | $114.6M | $81.3M | ||
| Q4 24 | $144.8M | $145.8M | ||
| Q3 24 | $144.7M | $137.0M | ||
| Q2 24 | $189.3M | $163.5M | ||
| Q1 24 | $226.6M | $220.5M |
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.6B | ||
| Q4 24 | $-388.7M | $1.8B | ||
| Q3 24 | $-370.2M | $1.9B | ||
| Q2 24 | $-344.2M | $2.0B | ||
| Q1 24 | $-294.3M | $2.1B |
| Q4 25 | $465.9M | $4.4B | ||
| Q3 25 | $364.0M | $4.4B | ||
| Q2 25 | $347.1M | $4.5B | ||
| Q1 25 | $324.0M | $4.7B | ||
| Q4 24 | $343.8M | $5.0B | ||
| Q3 24 | $314.1M | $5.2B | ||
| Q2 24 | $352.3M | $5.3B | ||
| Q1 24 | $373.1M | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $73.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $73.3M | ||
| Q3 25 | $-4.3M | $8.9M | ||
| Q2 25 | $-31.4M | $18.8M | ||
| Q1 25 | $-22.6M | $12.9M | ||
| Q4 24 | $-35.0M | $129.4M | ||
| Q3 24 | $-35.3M | $26.4M | ||
| Q2 24 | $-7.2M | $23.8M | ||
| Q1 24 | $53.8M | $37.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
JBGS
Segment breakdown not available.
